Integrated Drug Discovery
It is well knowing that drug discovery and development is a resource, cost and time intensive process. At YBL, we understand the need for an end-to-end support, right from target identification through to preclinical candidate selection. Our team of dedicated and multi-disciplinary scientists working in state-of-the-art facilities provides technical support and execution at each stage that enable rapid progress without compromise to quality. YBL’s scientists can support each key stage of the drug discovery process; from de novo assay development, assay optimization and miniaturization; tailored hit discovery approaches including fragment, focused, and diversity-based high-throughput screening; through to hits to lead and lead optimization. We provide a fully flexible and tailored solution to meet your needs, from stand-alone projects through to fully integrated drug discovery services with the capability to take your target from concept to candidate. Our customers include major pharma, biotech, health charities and academia. All intellectual property generated is owned by the customer.
Antibody Discovery and Development
Antibody discovery is challenging process. It differs from the traditional drug discovery of small molecules as it requires the development of hybridomas and the engineering of antibodies to recognize a specific target protein. Antibodies have recently emerged as an optimal diagnostic option for infectious diseases like COVID-19. To mount a successful monoclonal antibody (mAb)-based discovery and development program, whether developing therapeutic antibodies or antibody drug conjugates, you need technologies that allow rapid identification and characterization of candidate molecules to identify those with superior target reactivity and optimized functionality. YBL has developed a synthetic Camelid Single Domain Antibody (also referred as VHH or Nanobody) phage display library for recombinant monoclonal antibody development and manufacturing. It would offer quick, efficient and cost effective customized antibody discovery and manufacturing services to our esteemed customers.
Some of the salient features of the platform are as follows:
- Camelid SdAb (VHH) Synthetic Library of >1010 independent clones
- Controlled CDR mutagenesis using TRIM technology
- Library with 12 variables lengths of CDR3 between 6 – 20 amino acids to cover maximum diversity
- Fast turnover time for discovery – 8-10 weeks
- Flexibility in antibody format and engineering – Easy re-formating to make Human/rabbit/Mouse Fc – fused complete antibody, Bi-specific and multivalent antibody format.
- Target areas – Diagnostics biomarkers for Cancer, Cardiac, Neurological, Autoimmunity, Infectious diseases and Veterinary diagnostics.
Modern drug discovery, pre-clinical, demand reliable high-throughput assays for the detection of drug compounds in serum and other biological samples. Because of the complexity and longtime commitments involved in the development of such assays, particularly highly specific or efficient assays and immunoassays, many pharmaceutical companies, biotech, and academic institutions have found that it becomes a bottleneck, holding up valuable research.
YBL’s efficient and reliable antibody production and immunoassay development services provide a solution to this problem, delivering top-quality assays and freeing up necessary staff and facilities.
Cell Line Engineering
Creating stable cell lines is time-consuming and complex. The trusted, experienced team of scientists can custom-design stable cell lines using one of the most robust and reliable technologies on the market. Utilizing quality products throughout the process, our scientists will work with you to design your stable cell line and perform quality control testing to help ensure that the cell line meets your requirements. We have experience working with a wide variety of cell backgrounds. Every editing project is unique to the client, based on the modification desired and the cell background; therefore, we provide consultation services to evaluate the technical feasibility of editing in your desired cell line. We take the time to understand your goals. Our complete portfolio of solutions sets us apart and allows us to achieve maximum efficiencies. We optimize the cell culture conditions and transfection method, and we validate per your specifications, to help ensure you receive the edited cell line you desire. Our services were developed with you as our top priority. We provide a dedicated project manager who will work with you to help meet your research goals and timelines—we’re committed to helping you succeed.
Yashraj Biotechnology Ltd. (YBL) is an indigenous and innovative pioneer in the development of human biomarkers/antigens for point-of-care tests in the In Vitro Diagnostic (IVD) industry. The antigens of highest quality are rigorously tested to meet the demand in research and development. YBL provides antigens with uncompromising biological activity at competitive prices. As a leading supplier of antigens, YBL is proud to offer the highest quality antigens supported by extensive research, development, and validation. We are committed to the highest standards of product performance, and our scientists are dedicated to accelerating your discoveries.
Native antigens are extracted in their natural form from an appropriate source. They bear a very close resemblance when isolated to the complex 3-dimensional structure they exhibit in the body. In the case of protein antigens, these modifications can include post-translational alterations such as cleavage of precursor proteins, formation of disulphide bonds, and addition of low molecular weight groups through processes such as glycosylation or phosphorylation.
Recombinant antigens are manufactured artificially. A common method of achieving this is to transform a bacterium such as E. coli with a vector expressing the protein of interest, following which the expressed protein can be purified from the culture broth. To aid purification, recombinant antigens are often tagged with a moiety such as glutathione S-transferase (GST) or a polyhistidine tag (His). These tags may impact on protein folding. Furthermore, if the antigen is intended for use as an immunogen during antibody production, it may be necessary to remove anti-tag antibodies from the resulting preparation.
YBL has recently ventured in manufacturing of enzymes using fermentation technology. We are equipped with state-of-the-art manufacturing facilities and research & development centers at our India site to fulfil client needs